Based on its role in promoting T cell survival, persistence, and effector function, it is predicted that CAR T cells manufactured with interleukin-15 would exhibit **increased cytokine release** (e.g., higher levels of IFN-γ and TNF-α) upon encountering their target antigen compared to CAR T cells manufactured without interleukin-15.